Related Experiment Video
Updated: Jan 14, 2026
Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study
Published on: July 7, 2023
ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation
Óscar Monteagudo-García1,2, Paz Nombela1,2, Ángel Carlos Román3
1Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, Salamanca, Spain.
Abstract:
Aggressive metastatic cancer remains a major clinical challenge because of the unclear underlying mechanisms and the limited treatment options available. N6-Methyladenosine (m6A) is a reversible modification of RNA that is frequently altered in cancer, and inhibitors targeting regulators of this process have been shown to block tumorigenesis. A better understanding of the role of m6A modifications in driving metastatic properties could help reveal potential strategies to prevent and treat metastasis. In this study, we discovered loss of the m6A writer complex component ZC3H13 as a key regulator of metastatic progression. Co-loss of ZC3H13 together with RB1 and BRCA2 occurred in patients with metastatic prostate cancer. Functional in vitro and in vivo assays demonstrated that ZC3H13 loss changes m6A writer complex activity and target specificity, leading to decreased m6A methylation and increased stability of transcripts that promote migration and invasion. Treatment with FDA-approved m6A demethylase inhibitors effectively reduced the metastatic capabilities of ZC3H13-deficient cells. Together, these findings provide insights into how the m6A writer complex selectively methylates mRNAs, highlight the pathologic consequences of altered writer complex composition in cancer, and reveal therapeutic avenues for patients with metastatic cancer.
Significance:
FDA-approved m6A demethylase inhibitors can inhibit metastasis driven by ZC3H13 deficiency, which reduces m6A methylation of select transcripts involved in migration and invasion, providing potential therapeutic options for patients with metastatic cancer.
Insights
Loss of ZC3H13, an N6-methyladenosine (m6A) writer complex component, promotes cancer metastasis by altering RNA methylation. Targeting m6A demethylase inhibitors may offer new treatments for metastatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Metastatic cancer presents significant clinical challenges due to poorly understood mechanisms and limited therapies.
- N6-methyladenosine (m6A) RNA modification is frequently dysregulated in cancer, and its regulators are potential therapeutic targets.
- Understanding m6A's role in metastasis is crucial for developing novel treatment strategies.
Purpose of the Study:
- To investigate the role of m6A writer complex components in metastatic progression.
- To identify specific molecular mechanisms by which m6A alterations drive cancer metastasis.
- To evaluate the therapeutic potential of targeting m6A regulators in metastatic cancer.
Main Methods:
- Analysis of ZC3H13 expression in patient cohorts, particularly in metastatic prostate cancer.
- In vitro and in vivo functional assays to assess the impact of ZC3H13 loss on cell migration and invasion.
- Examination of m6A methylation levels and target mRNA stability following ZC3H13 manipulation.
- Treatment of ZC3H13-deficient cells with FDA-approved m6A demethylase inhibitors.
Main Results:
- Loss of ZC3H13, often co-occurring with RB1 and BRCA2 loss in metastatic prostate cancer, was identified as a key regulator of metastasis.
- ZC3H13 deficiency altered m6A writer complex activity, leading to reduced global m6A methylation.
- This reduction increased the stability of transcripts promoting cell migration and invasion.
- FDA-approved m6A demethylase inhibitors effectively suppressed the metastatic capabilities of ZC3H13-deficient cells.
Conclusions:
- ZC3H13 loss contributes to cancer metastasis through altered m6A methylation patterns and subsequent changes in mRNA stability.
- The findings elucidate the selective mRNA methylation mechanisms of the m6A writer complex and the pathological impact of its altered composition.
- Targeting m6A demethylases presents a promising therapeutic strategy for patients with metastatic cancers characterized by ZC3H13 deficiency.
Related Concept Videos
01:46Epigenetic Regulation
01:37Epigenetic Regulation
X-chromosome...
01:22MicroRNAs
01:22MicroRNAs
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...